I'm sharing information I ran across today in regard to clinical trials with Obeticholic Acid or OCA. The study showed that patients who received OCA in combination with ursodeoxycholic acid (UDCA), experienced a clinically meaningful improvement in serum alkaline phosphatase counts (ALP) and other measures of liver function, which can significantly lower the risk of progressing to liver failure. These results, along with the positive data from Intercept’s Phase II studies of OCA in PBC, provide further evidence that this treatment has the potential to result in important clinical benefit to PBC patients. Woohoo!
This provides an overview of the topline study results: globenewswire.com/news-rele...
Source: Cheya M. Pope, Senior Director, Patient Advocacy, Intercept Pharmaceuticals